Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07277608

Clinical Characteristics and Molecular Mechanism of Patients With Obstructive Sleep Apnea

To clarify the clinical features of patients with obstructive sleep apnea; To construct a multi-omics database of patients with obstructive sleep apnea, and compare the effects of different degrees of sleep apnea on prognosis, immunity, and metabolism. The medium and long-term prognosis, complications, comorbidities, risk factors, and immune and metabolic dynamics of patients with sleep apnea after treatment were studied. To elucidate the biomarkers and therapeutic targets associated with obstructive sleep apnea.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obstructive Sleep Apnea Apnea Dyssomnias Nervous System Diseases Respiration Disorders Respiratory Tract Diseases Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders

Sex eligibility

All sexes

Study type

Observational

Primary location

Beijing Chaoyang hospital affiliated to Capital Medical University

Beijing, Beijing Municipality, 100020, China

Location status: Recruiting

Location contact

Zhiling Zhao

CONTACT

[email protected]

+86 186 1280 8859

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with suspected obstructive sleep apnea (OSA) admitted to the sleep center of the respiratory Department of Beijing Chaoyang Hospital, Capital Medical University.
  • Volunteer to participate in the study and sign an informed consent, and can complete at least 1 year of follow-up.

Exclusion criteria

  • Patients with obstructive sleep apnea who have been treated with impermanent positive pressure ventilation;
  • Pregnant or lactating women;
  • Patients with severe respiratory failure requiring mechanical ventilation;
  • Patients with severe heart, lung, liver, kidney, and central nervous system damage;
  • Refuse to participate in follow-up visits and/or take biological samples.

Treatment and study plan

Primary outcomes

  1. Multiple-omics features

    Time frame: Within 24 hours of admission，and samples of patients receiving treatment were also collected six months and one year after treatment

    ELISA ,proteomics and metabolomics were performed on blood, saliva, urine

Study contacts

Contact information is provided by the study sponsor or research team.

Zhiling Zhao

CONTACT

[email protected]

+86 186 1280 8859

Sponsors and collaborators

Lead sponsor

Capital Medical University

Other

Registry information

Important dates

Study start
2023
Primary completion
2033
Study completion
2033
First posted
Dec 11, 2025
Registry last updated
Dec 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.